Literature DB >> 12393520

Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.

Fenghuang Zhan1, Erming Tian, Klaus Bumm, Ruston Smith, Bart Barlogie, John Shaughnessy.   

Abstract

To identify genes linked to normal plasma cell (PC) differentiation and to classify multiple myeloma (MM) with respect to the expression patterns of these genes, we analyzed global mRNA expression in CD19-enriched B cells (BCs) from 7 tonsils, CD138-enriched PCs from 11 tonsils, 31 normal bone marrow samples, and 74 MM bone marrow samples using microarrays interrogating 6800 genes. Hierarchical clustering analyses with 3288 genes clearly segregated the 4 cell types, and chi-square and Wilcoxin rank sum tests (P <.0005) identified 359 and 500 previously defined and novel genes that distinguish tonsil BCs from tonsil PCs (early differentiation genes [EDGs]), and tonsil PCs from bone marrow PCs (late differentiation genes [LDGs]), respectively. MM as a whole was found to have dramatically variable expression of EDGs and LDGs, and one-way analysis of variance (ANOVA) was used to identify the most variable EDGs (vEDGs) and LDGs (v1LDG and v2LDG). Hierarchical cluster analysis with these genes revealed that previously defined MM gene expression subgroups (MM1-MM4) could be linked to one of the 3 normal cell types. Clustering with 30 vEDGs revealed that 13 of 18 MM4 cases clustered with tonsil BCs (P =.000 05), whereas 14 of 15 MM3 cases clustered with tonsil PCs when using 50 v1LDG (P =.000 008), and 14 of 20 MM2 cases clustered with bone marrow PCs when using 50 v2LDG (P =.000 09). MM1 showed no significant linkage with normal cell types studied. Thus, genes whose expression is linked to distinct transitions in late-stage B-cell differentiation can be used to classify MM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393520     DOI: 10.1182/blood-2002-06-1737

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

Review 2.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

3.  CD19-positive antibody-secreting cells provide immune memory.

Authors:  C J Groves; J Carrell; R Grady; B Rajan; C A Morehouse; R Halpin; J Wang; J Wu; Y Shrestha; R Rayanki; R Kolbeck; Y Wang; R Herbst
Journal:  Blood Adv       Date:  2018-11-27

4.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

5.  The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

Authors:  Karin Tarte; Michel Jourdan; Jean Luc Veyrune; Ingolf Berberich; Geneviève Fiol; Nicole Redal; John Shaughnessy; Bernard Klein
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

6.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 7.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

Review 8.  Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Vincent S Rajkumar
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

9.  Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Emanuel N Husu; Costas Pitsillides; Steven Vesole; Abdel Kareem Azab; Feda Azab; Molly Melhem; Hai T Ngo; Phong Quang; Patricia Maiso; Judith Runnels; Mei-Chih Liang; Kwok-Kin Wong; Charles Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

Review 10.  Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.

Authors:  Alan C Rapraeger
Journal:  FEBS J       Date:  2013-02-24       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.